Earnings summaries and quarterly performance for VERACYTE.
Executive leadership at VERACYTE.
Board of directors at VERACYTE.
Research analysts who have asked questions during VERACYTE earnings calls.
PS
Puneet Souda
Leerink Partners
6 questions for VCYT
Also covers: A, ABCL, BRKR +20 more
LL
Lu Li
Scotiabank
5 questions for VCYT
Also covers: FLGT, HOLX, MYGN +2 more
AB
Andrew Brackmann
William Blair & Company, L.L.C.
4 questions for VCYT
Also covers: ADPT, AWH, BDSX +11 more
Subbu Nambi
Guggenheim Securities
4 questions for VCYT
Also covers: ADPT, BOLD, BRKR +17 more
Doug Schenkel
Wolfe Research LLC
3 questions for VCYT
Also covers: A, AVTR, BRKR +15 more
SJ
Sung Ji Nam
Scotiabank
3 questions for VCYT
Also covers: ADPT, BDSX, BNGO +9 more
Andrew Cooper
Raymond James
2 questions for VCYT
Also covers: AZTA, CDNA, CTKB +12 more
Ben Mee
Stephens
2 questions for VCYT
KM
Kyle Mikson
Canaccord Genuity
2 questions for VCYT
Also covers: AKYA, BDSX, CSTL +12 more
MC
Mason Carrico
Stephens Inc.
2 questions for VCYT
Also covers: AKYA, CDNA, CSTL +13 more
Mike Matson
Needham & Company, LLC
2 questions for VCYT
Also covers: CNMD, ENOV, ESTA +16 more
SN
Subhalaxmi Nambi
Guggenheim Securities
2 questions for VCYT
Also covers: AKYA, BRKR, CSTL +15 more
TS
Tejas Savant
Morgan Stanley
2 questions for VCYT
Also covers: ADPT, AKYA, AVTR +19 more
Thomas DeBourcy
Nephron Research
2 questions for VCYT
Also covers: CDNA, NEOG, QTRX +2 more
YO
Yuko Oku
Morgan Stanley
2 questions for VCYT
Also covers: ADPT, GH, GRAL +7 more
AB
Andrew Brackman
William Blair
1 question for VCYT
Also covers: BLLN, DGX, LH
CB
Colleen Babington
Wolfe Research, LLC
1 question for VCYT
Also covers: CARS, GRAL, NTRA +1 more
Corey Rosenbaum
Scotiabank
1 question for VCYT
Also covers: ADPT, CSTL
Douglas Schenkel
Wolfe Research, LLC
1 question for VCYT
Also covers: A, AVTR, BRKR +21 more
MB
Maggie Boeye
William Blair
1 question for VCYT
Also covers: QDEL, SERA, XGN
MS
Matt Sykes
Goldman Sachs Group, Inc.
1 question for VCYT
Also covers: CRL, CTKB, MRVI +4 more
Michael Matson
Needham & Company
1 question for VCYT
Also covers: AORT, ATRC, CNMD +22 more
Recent press releases and 8-K filings for VCYT.
Veracyte Provides 2025 Performance Expectations and 2026 Financial Guidance
VCYT
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Veracyte expects to achieve $515-$517 million in revenue for 2025, with approximately 17% testing revenue growth, and anticipates an Adjusted EBITDA of greater than 25% for the year.
- For 2026, the company forecasts total revenue between $570-$582 million, with core testing revenue of $559 million-$569 million (representing 14%-16% growth), and aims to maintain an Adjusted EBITDA margin of 25% or more.
- The company plans two significant product launches in 2026: True MRD for muscle-invasive bladder cancer in the first half, and ProSigna as an LDT for the U.S. market by mid-year.
- Core products, Decipher and Afirma, are expected to continue driving growth, with Decipher showing a 37% three-year revenue growth CAGR and projected strong double-digit growth in 2026 and beyond, while Afirma is projected for mid to high single-digit growth in 2026.
- Veracyte is also focused on geographic expansion through an IVD strategy and developing new solutions for cancer challenges, such as a nasal swab for lung cancer.
Jan 15, 2026, 5:45 PM
Veracyte Provides 2025 Financial Performance and 2026 Outlook at J.P. Morgan Healthcare Conference
VCYT
Guidance Update
Product Launch
New Projects/Investments
- Veracyte expects to deliver 2025 revenue in the range of $515-$517 million, driven by approximately 17% testing revenue growth, and anticipates achieving greater than 25% Adjusted EBITDA for the full year.
- For 2026, the company projects total revenue between $570-$582 million, with core testing revenue expected to be $559 million-$569 million, representing 14%-16% growth, and aims to maintain an industry-leading 25% Adjusted EBITDA margin.
- The company is advancing its product pipeline with planned launches in 2026, including True MRD for muscle-invasive bladder cancer in the first half, and ProSigna as an LDT for the U.S. market in mid-2026.
- Core products Decipher and Afirma continue to drive growth, with Decipher showing a three-year revenue growth CAGR of over 37% and Afirma achieving 11% volume growth in 2025; both tests are expected to have strong growth in 2026.
Jan 15, 2026, 5:45 PM
Veracyte Provides 2025 Financial Estimates and 2026 Guidance, Announces New Product Launches
VCYT
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Veracyte expects to report 2025 revenue between $515 million-$517 million, with approximately 17% testing revenue growth and greater than 25% Adjusted EBITDA, and projects 2026 total revenue of $570 million-$582 million with 14%-16% core testing revenue growth and a 25% Adjusted EBITDA margin.
- The company plans to launch True MRD for muscle-invasive bladder cancer in the first half of 2026 and ProSigna as an LDT for the U.S. breast cancer market in mid-2026.
- Core tests, Decipher and Afirma, are anticipated to continue strong growth in 2026, with Decipher projected for approximately 20% revenue growth and Afirma for mid to high single-digit growth, leveraging current market penetrations of 33% and 38% respectively.
Jan 15, 2026, 5:45 PM
Veracyte Announces Preliminary Q4 and Full-Year 2025 Results and 2026 Guidance
VCYT
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Veracyte (VCYT) announced preliminary, unaudited financial results for Q4 and full-year 2025 on January 11, 2026.
- For the full year ended December 31, 2025, the company expects to report total revenue between $515 million and $517 million, an increase of 16%, and an adjusted EBITDA margin of greater than 25%.
- For the fourth quarter ended December 31, 2025, total revenue is expected to be between $138 million and $140 million, an increase of 16% to 18%.
- Veracyte initiated 2026 total revenue guidance of $570 million to $582 million, representing 10% to 13% growth, with an expected adjusted EBITDA margin of 25%.
Jan 12, 2026, 11:05 AM
Veracyte Announces Preliminary Q4 and Full-Year 2025 Results
VCYT
Earnings
Guidance Update
Product Launch
- Veracyte announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.
- For full-year 2025, the company expects to report total revenue between $515 million and $517 million, a 16% increase, and an adjusted EBITDA margin of greater than 25%.
- For the fourth quarter of 2025, total revenue is expected to be between $138 million and $140 million, an increase of 16% to 18%.
- Veracyte is initiating 2026 total revenue guidance of $570 million to $582 million, representing 10% to 13% growth, with an expected adjusted EBITDA margin of 25%.
- The company plans to launch Prosigna and its TrueMRD platform in the US market in 2026.
Jan 11, 2026, 9:30 PM
Veracyte Reports Strong Q3 Results, Raises Full-Year Adjusted EBITDA Guidance, and Outlines Product Pipeline
VCYT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Veracyte reported strong Q3 results with over $131 million in revenue, representing 14% growth, primarily driven by its testing business which grew 17%.
- The company achieved 30% adjusted EBITDA in Q3, leading to an increased full-year guidance of over 25% adjusted EBITDA, a long-term goal met ahead of expectations.
- Key product lines, Decipher and Afirma, showed robust performance, with Decipher growing over 25% for the 14th consecutive quarter and Afirma volumes increasing 13% in Q3.
- Veracyte is preparing for the launch of the Prosigna LDT in mid-2026 and the TruMRD assay for muscle invasive bladder cancer in the first half of next year, while also transitioning Afirma to the V2 Transcriptome for improved efficiency.
- The company expects to end the year with nearly $400 million in cash and no debt, prioritizing investments in strategic growth drivers over M&A.
Nov 20, 2025, 5:00 PM
Veracyte Reports Strong Q3 Results, Raises Guidance, and Details Product Pipeline
VCYT
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Veracyte reported strong Q3 2025 results, with revenue exceeding $131 million, a 14% increase, and achieved 30% adjusted EBITDA, leading to an increased full-year guidance for both revenue and adjusted EBITDA to over 25%.
- The company's testing business grew 17%, with Decipher achieving its 14th consecutive quarter of over 25% growth and Afirma volumes increasing 13% in Q3.
- Veracyte is transitioning to its new V2 Transcriptome, with almost a third of samples running on it in Q3 and a goal for full transition by year-end, which is expected to improve cost efficiency and increase valid test results.
- Upcoming product launches include TruMRD for muscle invasive bladder cancer in the first half of 2026 and the Prosigna LDT in mid-2026, with strategic investments planned for their commercialization.
- The company is in a strong financial position with nearly $400 million in cash and no debt, prioritizing investments in strategic growth drivers such as Afirma, Decipher, Prosigna, LDT, MRD, and IBD.
Nov 20, 2025, 5:00 PM
Veracyte Reports Strong Q3 Performance and Updates on Product Pipeline
VCYT
Guidance Update
Product Launch
New Projects/Investments
- Veracyte reported a strong Q3 with over $131 million in revenue, a 14% increase, driven by 17% growth in its testing business.
- The company achieved 30% adjusted EBITDA in Q3, leading to an increased full-year guidance to over 25% adjusted EBITDA, ahead of its long-term goal.
- Key product updates include Decipher growing over 25% for the 14th consecutive quarter, Afirma volumes up 13%, and the V2 transcriptome transition for Afirma expected to be complete by year-end.
- Veracyte plans to launch TruMRD for muscle invasive bladder cancer in the first half of next year and the Prosigna LDT in mid-2026, with the OPTIMA trial results expected to provide level one evidence for Prosigna.
- The company expects to end the year with close to $400 million in cash and no debt, maintaining its 25% adjusted EBITDA margin target for 2026 and beyond.
Nov 20, 2025, 5:00 PM
Veracyte Reports Strong Q3 2025 Performance and Outlines 2026 Product Pipeline
VCYT
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Veracyte reported strong Q3 2025 performance, with total company revenue growing 14% year-over-year and the testing business growing 18% (adjusted for a portfolio decision). The company achieved an adjusted EBITDA margin of 30%, exceeding its 25% target more than a year early.
- The company plans significant product launches in 2026, including a differentiated whole genome MRD test in the first half (starting with muscle-invasive bladder cancer) and the Prosigna test as a lab-developed test for the U.S. market in the middle of the year.
- The class-leading Decipher test continued its strong momentum, achieving 26% volume growth in Q3 2025, marking its 14th consecutive quarter of over 25% growth, with 75% of the prostate cancer market still unaddressed.
- Afirma also demonstrated strong performance with 13% volume growth in Q3 2025. Starting January 1 (presumably 2026), all Afirma samples will utilize a new transcriptome, which is expected to significantly reduce costs.
Nov 20, 2025, 11:30 AM
Veracyte Reports Strong Q3 Performance and Outlines 2026 Product Launches
VCYT
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Veracyte reported strong Q3 performance, with total company revenue growth of 14% year-over-year and testing business growth of 18% (excluding Invisia test adjustment). The company achieved an adjusted EBITDA margin of 30% and raised revenue and profitability guidance.
- The Decipher test demonstrated 26% volume growth in Q3, marking its 14th consecutive quarter of over 25% growth, and holds approximately 65% market share with 25% market penetration in the US prostate cancer diagnostic market. The Afirma test grew 13% in volume in Q3.
- The company plans to launch its MRD test in the first half of 2026, starting with muscle-invasive bladder cancer, and its Prosigna test as a lab-developed test (LDT) for the US market in the middle of 2026, targeting approximately 225,000 patients annually.
- Veracyte expects 300-500 basis point accretion to Decipher's average selling price (ASP) over the next five years, driven by increased commercial payer coverage aiming for 250-275 million covered lives.
Nov 20, 2025, 11:30 AM
Quarterly earnings call transcripts for VERACYTE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more